Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BioAge Labs
Biotech
BioAge brings in $198M from IPO as obesity biotech joins Nasdaq
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO, with proceeds earmarked for taking its obesity drug further into clinical trials.
James Waldron
Sep 26, 2024 4:44am
BioAge eyes $180M from IPO, private placement for obesity trials
Sep 25, 2024 7:55am
UPDATE: Lilly-backed metabolic disease biotech files IPO
Sep 4, 2024 10:23am
Ex-GSK CEO takes up board post at aging, obesity biotech BioAge
Aug 22, 2024 10:09am
Sands Capital raises new $555M life sci fund
May 14, 2024 10:30am
GLP-1 enthusiasm pushes BioAge into new age with $170M series D
Feb 13, 2024 8:00am
